Fax +41 61 306 12 34 E-Mail karger@karger.ch www.karger.com Neuroendocrine Tumors Neuroendocrinology 2009;89:217–222 DOI: 10.1159/000151562 Thirteen-Month Registration of Patients with Gastroenteropancreatic Endocrine Tumours in France C. Lombard-Bohas a E. Mitry b D. O’Toole c C. Louvet d D. Pillon e G. Cadiot f F. Borson-Chazot g T. Aparicio h M. Ducreux i T. Lecomte j P.L. Etienne k W. Cacheux l J.L. Legoux m J.F. Seitz n P. Ruszniewski c J.A. Chayvialle a P. Rougier b for FFCD-ANGH-GERCOR a Hôpital E. Herriot, HCL Lyon, b Hôpital A. Paré, APHP Boulogne, c Hôpital Beaujon, APHP Clichy, d Hôpital Saint Antoine, APHP Paris, e CH Bourg en Bresse, f CHU R. Debré, Reims, g GHE, HCL Lyon, h Hôpital Bichat, APHP Paris, i Institut G. Roussy Villejuif, j HEG Pompidou, APHP Paris, k Clinique Armoricaine St Brieuc, l Hôpital Cochin, APHP Paris, m CHU Bordeaux, Pessac, n CHU la Timone, Marseille, France statin analogues: 44 and 26% for GEP of small intestine and pancreas, respectively; interferon: 12%, and intra-arterial he- patic (chemo)embolization in 23 and 15% of GEP arising from the midgut and pancreas, respectively. Despite their low prevalence, well-differentiated GEP represent a significant and heterogeneous clinical group, which warrants improved medical education, referral to expert centres at an early stage, and the design of prospective therapeutic trials. Copyright © 2008 S. Karger AG, Basel Introduction Gastroenteropancreatic endocrine tumours (GEP) are a heterogeneous group of tumours characterized by com- mon morphological and functional features. They are currently classified according to the WHO histoprognos- tic classification in three subgroups, namely benign en- docrine tumours, well-differentiated carcinomas and Key Words Digestive endocrine tumours  Endocrine tumours, epidemiology  Endocrine tumours, France Abstract The prevalence, clinical profiles and management of gastro- enteropancreatic endocrine tumours (GEP) in France are not known. From August 1, 2001 to September 1, 2002, standard- ized records on patients with GEP were prospectively com- pleted in 87 participating centres. The total group amounted to 668 patients (median age: 56 years, range: 12–89). WHO performance status was 0/1 for 80.2% of patients. The pri- mary sites were the small bowel and colon (288), pancreas (211), unknown (77), stomach (33), non-digestive primary sites (24), appendix (20), rectum-anus (12), and oesophagus or cardia (3). GEP were functional in 260 patients (39%). Most pancreatic tumours were non-functional (72%). Metastatic disease was observed in 73.4% of cases. Most tumours (85.8%) were well or moderately differentiated. Somatostatin recep- tor scintigraphy was performed in only 55% of patients. The following treatment modalities were employed: resection of primary tumour: 66%; systemic chemotherapy: 41%; somato- Received: February 25, 2008 Accepted after revision: May 9, 2008 Published online: August 22, 2008 Catherine Lombard-Bohas Medical Oncology, Pavillon H – Hôpital Edouard Herriot Place d’Arsonval FR–69437 Lyon cedex 03 (France) Tel. +33 4 7211 0093, Fax +33 4 7222 9153, E-Mail catherine.lombard@chu-lyon.fr © 2008 S. Karger AG, Basel 0028–3835/09/0892–0217$26.00/0 Accessible online at: www.karger.com/nen C. Lombard-Bohas and E. Mitry contributed equally to this work.